Proresolution Lipid Mediators in Multiple Sclerosis — Differential, Disease Severity-Dependent Synthesis — A Clinical Pilot Trial
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The severity and longevity of inflammation is controlled by endogenous counter-regulatory signals. Among them are long-chain polyunsaturated fatty acid (PUFA)-derived lipid mediators, which promote the resolution of inflammation, an active process for returning to tissue homeostasis. OBJECTIVE: To determine whether endogenous production of lipid-derived resolution agonists is regulated differentially in patients with highly active and less active multiple sclerosis (MS). DESIGN: Matched-pairs study in University hospital Neurology department. PATIENTS: Based on clinical (relapse frequency) and paraclinical (MRI lesions, contrast enhancement) criteria, 10 pairs of age- and sex-matched patients with relapsing-remitting MS were assigned either to a group with highly active or less active MS. Lipid mediators were quantified in serum and cerebrospinal fluid using LC-MS/MS-based lipidomics. RESULTS: Levels of the key arachidonic (ω-6) and docosahexaenoic acid (ω-6)-derived mediators prostaglandins (PG), leukotrienes, hydroxyeicosatetraenoic acids (HETE) and resolution agonists lipoxin A(4) (LXA(4)), resolvin D1 (RvD1) and neuroprotectin D1 (NPD1) were quantified. In the patient group with highly active MS, 15-HETE and PGE(2) were increased, which are products of the 15-lipoxygenase and cyclooxygenase pathways. The proresolution mediator RvD1 was significantly upregulated and NPD1 was detected in the highly active group only. LXA(4) levels were not increased in patients with highly active MS. CONCLUSIONS: Lipid mediator pathways are regulated differentially in the cerebrospinal fluid of MS patients, depending on disease severity. Non-exhaustive or possibly 'delayed' resolution pathways may suggest a defective resolution program in patients with highly active MS. Longitudinal analyses are required to hetero-typify this differential resolution capacity, which may be associated with disease progression, longevity and eventual termination.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22366 · Cited by 9,802
Resolution of inflammation: the beginning programs the end
Serhan, C. N., & Savill, J. (2005) · Nature Immunology · doi:10.1038/ni1276 · Cited by 2,552 · cited 3×
“[1] It is a tightly controlled, directed tissue response orchestrated by cellular and humoral factors such as PUFA (omega- 3 (v-3), -6 (v-6))derived lipid mediators.”
BackgroundInfluentialNathan, C., & Ding, A. (2010) · Cell · doi:10.1016/j.cell.2010.02.029 · Cited by 2,183
Lipid mediator class switching during acute inflammation: signals in resolution
Levy, B. D., Clish, C. B., Schmidt, B., Gronert, K., & Serhan, C. N. (2001) · Nature Immunology · doi:10.1038/89759 · Cited by 1,453 · cited 1×
“Furthermore, since endogenous LXA4 synthesis is limited despite sufficient substrate (15-HETE) which is in line with a defective ‘‘lipid mediator class switch’’ [18], it might be worthwhile analyzing whether aspirin-triggered epimeric LXA4 levels can also be boosted in the CSF of MS patients, as has been demonstrated…”
BackgroundSelf-citation
Cited by
Pro-resolving lipid mediators are leads for resolution physiology
Serhan, C. N. (2014) · Nature · doi:10.1038/nature13479 · Cited by 3,041
Lipidomics: Techniques, Applications, and Outcomes Related to Biomedical Sciences
Yang, K., & Han, X. (2016) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2016.08.010 · Cited by 588
The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution
Serhan, C. N., Chiang, N., & Dalli, J. (2015) · Seminars in Immunology · doi:10.1016/j.smim.2015.03.004 · Cited by 583
Lipid Mediators in the Resolution of Inflammation
Serhan, C. N., Chiang, N., Dalli, J., & Levy, B. D. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016311 · Cited by 544
Bioactive lipids, inflammation and chronic diseases
Leuti, A., Fazio, D., Fava, M., Piccoli, A., Oddi, S., & Maccarrone, M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.028 · Cited by 358
Resolution of inflammation: An organizing principle in biology and medicine
Panigrahy, D., Gilligan, M. M., Serhan, C. N., & Kashfi, K. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107879 · Cited by 340
DHA- and EPA-derived resolvins, protectins, and maresins in airway inflammation
Duvall, M. G., & Levy, B. D. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.11.001 · Cited by 286
Prostaglandin‐cytokine crosstalk in chronic inflammation
Yao, C., & Narumiya, S. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14530 · Cited by 283
Schwab, J. M., Zhang, Y., Kopp, M. A., Brommer, B., & Popovich, P. G. (2014) · Experimental Neurology · doi:10.1016/j.expneurol.2014.04.023 · Cited by 260
“This appears to be true even in patients with multiple sclerosis (MS), an inflammatory human CNS disease with comparatively less tissue damage (Prüss et al., 2013).”
BackgroundSelf-citationSerhan, C. N. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.03.001 · Cited by 257
Dalli, J., & Serhan, C. N. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14336 · Cited by 138
“For example, in cerebrospinal fluids from patients with multiple sclerosis PGE2 and RvD1 concentrations were present at similar concentrations (~1 pg·mL (1)) (Pruss et al., 2013).”
BackgroundBioactive products formed in humans from fish oils
Skarke, C., Alamuddin, N., Lawson, J. A., Li, X., Ferguson, J. F., Reilly, M. P., & FitzGerald, G. A. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m060392 · Cited by 109
Broos, J. Y., van der Burgt, R. T. M., Konings, J., Rijnsburger, M., Werz, O., de Vries, H. E., Giera, M., & Kooij, G. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02981-w · Cited by 41
“These findings are in line with other studies, where increased levels of 15-HETE were observed in CSF and plasma of PwMS [20, 23, 37].”
BackgroundResultBroos, J. Y., Loonstra, F. C., de Ruiter, L. R. J., Gouda, M., Fung, W. H., Schoonheim, M. M., Heijink, M., Strijbis, E. M. M., Teunissen, C., Killestein, J., et al. (2023) · Neurology · doi:10.1212/wnl.0000000000207459 · Cited by 29
Natarajan, C., Le, L. H. D., Gunasekaran, M., Tracey, K. J., Chernoff, D., & Levine, Y. A. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2322577121 · Cited by 20
Metadata
- Authors
- Prüss, H., Rosche, B., Sullivan, A. B., Brommer, B., Wengert, O., Gronert, K., & Schwab, J. M.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-02-08
- Volume
- 8
- Issue
- 2
- Pages
- e55859
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W1996484957
- Cited by
- 103
- References
- 4
- FWCI
- 5.77
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.